1. Molecular characterization of patients with chronic hepatitis C virus infection in Jordan: implications on response to direct-acting antiviral therapy
- Author
-
Ana Fuentes, Issa Abu-Dayyeh, Adolfo de Salazar, Rehab Khasharmeh, Fatima Al-Shabatat, Samer Jebrin, Natalia Chueca, Faris M. Hamdan, Yazan Albtoush, Omar Abu Al-Shaer, Mohammed M. Rashid, Oday AlMohsen, Mohammad Al-Jbour, Amid Abdelnour, and Federico García
- Subjects
HCV ,Unusual genotype ,MENA ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: To investigate the molecular characteristics of Hepatitis C Virus (HCV) detected in patients with chronic HCV infection in Jordan. Methods: The study included 48 Jordanian treatment-naïve patients with active chronic HCV recruited from seven governorates. HCV genotype and the resistance-associated substitutions (RAS) profile were investigated by next-generation sequencing of the NS5B, NS5A, and NS3 regions of HCV. Results: “Unusual genotype 4 subtypes” were detected in four (8.3%) patients (4n-n = 1, 4o-n = 2, 4v-n = 1); one patient (2.1%) was co-infected by genotypes 1b+4a. Overall prevalence of NS5A RASs was 38.3% (3% cutoff); genotype 4a showed the highest NS5A RAS prevalence (n = 11, 55.0%). Overall prevalence of NS3 RASs was 21.8% (7/32), all genotype 1a-infected patients. Conclusions: We report, for the first time in Jordanian patients with chronic HCV infection, the detection of unusual genotype 4 subtypes 4n, 4o, and 4v. Baseline RASs in NS5A are frequent, with complex RASs patterns in some of the unusual subtypes. Our data support the need for sequencing surveillance programs in sub-Saharan Africa, Asia, and the Middle East and North African region to monitor response to treatment in these subtypes and to facilitate the World Health Organization's 2030 elimination strategy.
- Published
- 2023
- Full Text
- View/download PDF